FILTER

Refine your search with the following facets to narrow down your results.

7 Current news of 4-Antibody

4-Antibody AG and Evotec AG Form Strategic Collaboration

10-May-2012 - 4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high ...

antibodies drug discovery Evotec

4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration

21-Sep-2011 - 4-Antibody AG announced the successful completion of a second milestone in its ongoing collaboration with Boehringer Ingelheim. This second milestone triggered an undisclosed fee payment. 4-Antibody’s R&D collaboration with Boehringer Ingelheim commenced in early 2010 and is a long-term ...

Boehringer Ingelheim cooperations human antibodies +2

4-Antibody AG Forms Multi-target Oncology Research and Development Alliance with the Ludwig Institute

26-May-2011 - 4-Antibody AG announced the signing of a multi-target research alliance with the Ludwig Institute for Cancer Research (LICR). Under the terms of the deal, the focus of the research and clinical development alliance will be on a series of molecular targets which are important in the suppression of ...

cancer therapeutic antibodies

4-Antibody AG to Relocate to New Labs in Basel

09-May-2011 - 4-Antibody AG announced that the Company will be relocating its Basel head offices and labs in June 2011 to the newly opened Technology Park Basel, which is part of the Stücki Business Park in Basel-Kleinhüningen.The company’s new location is part of a new facility being opened by Councillor ...

4-Antibody AG Announces New Board Appointment

24-Jan-2011 - 4-Antibody AG announced the appointment of Dr Thomas von Rüden to its Board of Directors. Dr von Rüden was formerly CEO at DIREVO Industrial Biotechnology GmbH, Cologne, Germany. Before this, he was the Chairman of DIREVO’S Advisory Board and worked as President and Chief Executive Officer at ...

4-Antibody appoints Dr. Richard Mason as new Chief Executive Officer

01-Oct-2008 - 4-Antibody AG announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschäftsführer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence. Previously Dr. Mason was ...

AstraZeneca biotechnology business development +3

4-Antibody AG closes CHF 6 Million Series A financing and appoints Sijmen de Vries as CEO

23-Aug-2006 - 4-Antibody announced the closing of a CHF 6 million Series A financing and the appointment of Sijmen de Vries MD, MBA as its new CEO. The Series A financing was provided by a consortium of existing investors including Biomedinvest AG (CH), Grazia Equity (D), Life Science Partners (NL) and ...

Germany Life Sciences Novartis